0001012975-20-000119.txt : 20200212 0001012975-20-000119.hdr.sgml : 20200212 20200212175637 ACCESSION NUMBER: 0001012975-20-000119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200211 FILED AS OF DATE: 20200212 DATE AS OF CHANGE: 20200212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P. CENTRAL INDEX KEY: 0001634632 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 20605834 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic GP II, L.P. CENTRAL INDEX KEY: 0001729409 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 20605835 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: venBio Global Strategic GP II, Ltd. CENTRAL INDEX KEY: 0001729408 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 20605836 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Adelman Robert J CENTRAL INDEX KEY: 0001329161 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 20605837 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GOODMAN COREY S CENTRAL INDEX KEY: 0001278411 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 20605838 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-02-11 0001744659 Akero Therapeutics, Inc. AKRO 0001634632 venBio Global Strategic Fund II L.P. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 0001729409 venBio Global Strategic GP II, L.P. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 0001729408 venBio Global Strategic GP II, Ltd. 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 0001329161 Adelman Robert J 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 0001278411 GOODMAN COREY S 1700 OWENS STREET, SUITE 595 SAN FRANCISCO CA 94158 0 0 1 0 Common Stock 2020-02-10 4 S 0 7836 27.0761 D 3225861 I See footnote Common Stock 2020-02-11 4 S 0 2184 27.0458 D 3233677 I See footnote Common Stock 2020-02-12 4 S 0 6 27.14 D 3233671 I See footnote The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact 2020-02-10 venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact 2020-02-10 venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact 2020-02-10 Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2020-02-10 Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact 2020-02-10